These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 22632371)

  • 1. Quality of life in Graves' ophthalmopathy.
    Wiersinga WM
    Best Pract Res Clin Endocrinol Metab; 2012 Jun; 26(3):359-70. PubMed ID: 22632371
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of the National Eye Institute visual function questionnaire in Graves' ophthalmopathy.
    Bradley EA; Sloan JA; Novotny PJ; Garrity JA; Woog JJ; West SK
    Ophthalmology; 2006 Aug; 113(8):1450-4. PubMed ID: 16769116
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Validity and reliability of the TED-QOL: a new three-item questionnaire to assess quality of life in thyroid eye disease.
    Fayers T; Dolman PJ
    Br J Ophthalmol; 2011 Dec; 95(12):1670-4. PubMed ID: 21951566
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of quality of life in patients with Graves´ ophthalmopathy, before and after orbital decompression.
    Iacobæus L; Sahlin S
    Orbit; 2016 Jun; 35(3):121-5. PubMed ID: 27159575
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quality of life improves after strabismus surgery in patients with Graves' orbitopathy.
    Jellema HM; Merckel-Timmer E; Kloos R; Saeed P; Mourits MP
    Eur J Endocrinol; 2014 May; 170(5):785-9. PubMed ID: 24493116
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quality of life assessment in patients with Graves' disease and progressive infiltrative ophthalmopathy during combined treatment with methylprednisolone and orbital radiotherapy.
    Kulig G; Andrysiak-Mamos E; Sowińska-Przepiera E; Kulig J; Karakiewicz B; Brodowski J; Robaczyk M; Homa K; Letkiewicz M; Syrenicz A
    Endokrynol Pol; 2009; 60(3):158-65. PubMed ID: 19569015
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessing quality of life in Taiwanese patients with Graves' ophthalmopathy.
    Lin IC; Lee CC; Liao SL
    J Formos Med Assoc; 2015 Nov; 114(11):1047-54. PubMed ID: 24434244
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of Graves' ophthalmopathy on quality of life.
    Wiersinga WM; Prummel MF; Terwee CB
    J Endocrinol Invest; 2004 Mar; 27(3):259-64. PubMed ID: 15165002
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interpretation and validity of changes in scores on the Graves' ophthalmopathy quality of life questionnaire (GO-QOL) after different treatments.
    Terwee CB; Dekker FW; Mourits MP; Gerding MN; Baldeschi L; Kalmann R; Prummel MF; Wiersinga WM
    Clin Endocrinol (Oxf); 2001 Mar; 54(3):391-8. PubMed ID: 11298093
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Psychosocial and Clinical Outcomes of Orbital Decompression Surgery for Thyroid Eye Disease and Predictors of Change in Quality of Life.
    Wickwar S; McBain H; Ezra DG; Hirani SP; Rose GE; Newman SP
    Ophthalmology; 2015 Dec; 122(12):2568-76.e1. PubMed ID: 26421706
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessing quality of life in Australian patients with Graves' ophthalmopathy.
    Park JJ; Sullivan TJ; Mortimer RH; Wagenaar M; Perry-Keene DA
    Br J Ophthalmol; 2004 Jan; 88(1):75-8. PubMed ID: 14693779
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Establishing the usefulness of the GO-QOL in a UK hospital-treated population with thyroid eye disease in the CIRTED trial.
    Dietrich A; Taylor P; White P; Wilson V; Uddin J; Lee RWJ; Dayan C; Jackson S;
    Psychol Health Med; 2018; 23(sup1):1341-1355. PubMed ID: 30092670
    [TBL] [Abstract][Full Text] [Related]  

  • 13. GO-QOL--disease-specific quality of life questionnaire in Graves' orbitopathy.
    Sawicka-Gutaj N; Bednarczuk T; Daroszewski J; Waligórska-Stachura J; Miśkiewicz P; Sowiński J; Bolanowski M; Ruchała M
    Endokrynol Pol; 2015; 66(4):362-6. PubMed ID: 26323474
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Evaluation of quality of life in patients with Graves orbitopathy and its influencing factors].
    Weng CY; Li ZF; Hu SD; Luo YS; Feng XT; Zhong Q; Zhang Q; Shen J
    Zhonghua Nei Ke Za Zhi; 2019 Aug; 58(8):577-583. PubMed ID: 31365979
    [No Abstract]   [Full Text] [Related]  

  • 15. [Corticosteroids and radiotherapy in the treatment of Graves' ophthalmopathy].
    Nasr E; Khater S; Nehme-Nasr D; Azoury F; Jambart S
    J Med Liban; 2010; 58(2):86-90. PubMed ID: 20549894
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessing Graves' ophthalmopathy-specific quality of life in Korean patients.
    Choi YJ; Lim HT; Lee SJ; Lee SY; Yoon JS
    Eye (Lond); 2012 Apr; 26(4):544-51. PubMed ID: 22241019
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Related quality of life questionnaire specific to dysthyroid ophthalmopathy evaluated in a population of patients with Graves' disease.
    Delfino LC; Zunino A; Sapia V; Croome MDCS; Ilera V; Gauna AT
    Arch Endocrinol Metab; 2017; 61(4):374-381. PubMed ID: 28225858
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Psychosocial morbidity of Graves' orbitopathy.
    Kahaly GJ; Petrak F; Hardt J; Pitz S; Egle UT
    Clin Endocrinol (Oxf); 2005 Oct; 63(4):395-402. PubMed ID: 16181231
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Graves' ophthalmopathy: the clinical and psychosocial outcomes of different medical interventions - a systematic review.
    Bello OM; Druce M; Ansari E
    BMJ Open Ophthalmol; 2024 Jun; 9(1):. PubMed ID: 38886120
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The relationship between quality of life, cognition, and thyroid status in Graves' disease.
    Riguetto CM; Neto AM; Tambascia MA; Zantut-Wittmann DE
    Endocrine; 2019 Jan; 63(1):87-93. PubMed ID: 30173328
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.